Anzeige
Mehr »
Mittwoch, 10.09.2025 - Börsentäglich über 12.000 News
Warum diese Aktie jetzt das perfekte Chance-Risiko-Profil für Investoren bietet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1KAVV | ISIN: IE00B91XRN20 | Ticker-Symbol: 0PT
Tradegate
09.09.25 | 20:16
7,050 Euro
-2,76 % -0,200
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
PROTHENA CORPORATION PLC Chart 1 Jahr
5-Tage-Chart
PROTHENA CORPORATION PLC 5-Tage-Chart
RealtimeGeldBriefZeit
7,0007,20009.09.
7,1007,15009.09.

Aktuelle News zur PROTHENA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.09.Prothena stock price target lowered to $11 at Citizens JMP on ARIA concerns1
02.09.Prothena: Citizens JMP senkt Kursziel wegen ARIA-Bedenken auf 11 Dollar3
28.08.Prothena Corporation plc: Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference362Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
► Artikel lesen
28.08.Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study7
28.08.Piper Sandler slashes Prothena stock price target to $15 from $81 on PRX012 data4
PROTHENA Aktie jetzt für 0€ handeln
28.08.What 4 Analyst Ratings Have To Say About Prothena Corp4
28.08.Prothena's Alzheimer's trial hit by ARIA showstopper, resulting in 'non-competitive' profile4
27.08.PROTHENA CORP PUBLIC LTD CO - 8-K, Current Report1
27.08.Prothena Corporation plc: Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program323As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibody Phase 1 ASCENT clinical...
► Artikel lesen
08.08.PROTHENA CORP PUBLIC LTD CO - S-8, Securities to be offered to employees in employee benefit plans1
06.08.Novo Nordisk boosts Prothena on plans for amyloidosis therapy84
06.08.Prothena Corporation plc: Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy372Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Novo Nordisk successfully completed a Phase 2 trial with coramitug...
► Artikel lesen
05.08.Prothena stock price target lowered to $10 at RBC on program discontinuation3
05.08.9 Analysts Assess Prothena Corp: What You Need To Know2
05.08.Prothena: JMP Securities bleibt optimistisch vor wichtigen Alzheimer-Daten5
05.08.JMP reiterates Market Outperform rating on Prothena stock ahead of key data1
04.08.Prothena GAAP EPS of -$2.34 misses by $0.55, revenue of $4.42M misses by $0.94M1
04.08.Prothena Corporation plc: Prothena Reports Second Quarter 2025 Financial Results and Business Highlights348Net cash used in operating and investing activities was $46.4 million in the second quarter and net cash used in operating and investing activities was $99.8 million for the first six months of...
► Artikel lesen
01.08.A Glimpse of Prothena Corp's Earnings Potential1
30.07.PROTHENA CORP PUBLIC LTD CO - 8-K, Current Report3
Weiter >>
73 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1